Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATHE
HoldAlterity Therapeutics Limited · Healthcare · Australia · $82M · Avg Vol: $65K/d
COMPANY DESCRIPTION
Alterity Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative disorders. The company's competitive position is anchored by its lead drug candidate, ATH434, which targets the underlying pathology of Parkinsonian disorders like Multiple System Atrophy (MSA). Alterity operates as a highly specialized niche player in the orphan drug space, leveraging proprietary science to address significant unmet medical needs in neurology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 2.0M | 1.5M | — |
| EPS | -6.05 | -6.60 | -12.94 | -8.23 | — | — | — | — | — |
| Shares | 18.1M | 18.1M | 18.1M | 18.1M | 0.0% | 18.1M | — | — | — |
| Debt | 84.2K | 0.2M | 0.1M | 0.1M | 9.8% | 70.7K | — | — | — |
| Equity | 25.4M | 16.3M | 9.9M | 30.4M | 6.1% | — | — | — | — |
| Op CF | -8.8M | -14.4M | -9.0M | -8.2M | — | -9.8M | — | — | — |
| Inv CF | -63.9K | -26.1K | -4.1K | -5.4M | — | — | — | — | — |
| Fin CF | 11.7M | 89.1K | 6.6M | 28.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATHE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATHE | Alterity Therapeutics Limited(you) | $82M | 55 | Hold |
| AVE.AX | Avecho Biotechnology Limited | $64M | 42 | Hold |
| SPL.AX | Starpharma Holdings Limited | $244M | 49 | Hold |
| KZIA | Kazia Therapeutics Limited | $155M | 36 | Hold |
| ATX.AX | Amplia Therapeutics Limited | $53M | 30 | Sell |
| LTP.AX | LTR Pharma Limited | $61M | 24 | Sell |
| BLS.AX | BLS Pharmaceuticals Limited | $152M | 79 | Buy |
| ILA.AX | Island Pharmaceuticals Limited | $93M | 19 | Strong Sell |
| PTX.AX | Prescient Therapeutics Limited | $50M | 22 | Sell |
| ACW.AX | Actinogen Medical Limited | $118M | 18 | Strong Sell |
Peer medians: ROE -19.4% · P/E 34.6x · Gross margin 60.5%